Back HCV Disease Progression Liver Cancer/HCC

Liver Cancer/HCC

Coverage of the 2015 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 2015 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in San Francisco, November 13-17, 2015.

Conference highlights include interferon-free therapy for hepatitis C, treatment for difficult-to-treat populations including people with HCV genotype 3 and liver  cirrhosis, hepatitis B prevention and treatment, and management of advanced liver disease.

Full listing by topic

Liver Meeting website

11/23/15

alt

AASLD 2015: People with Cirrhosis Cured of Hepatitis C Still Have Elevated Liver Cancer Risk

The burden of liver cancer and cirrhosis caused by hepatitis C virus (HCV) is likely to continue to grow in the U.S. despite curative treatment, and people who have cirrhosis at the time they are cured of hepatitis C will require long-term monitoring for liver cancer, studies presented this week at the AASLD Liver Meeting in San Francisco show.

alt

Read more:

ASCO 2015: PD-1 Checkpoint Inhibitor Nivolumab Shows Promise against Liver Cancer

Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor nivolumab (Opdivo) was a star of the show at the American Society of Clinical Oncology (ASCO) annual meeting this week in Chicago, with study results showing that the drug demonstrated anti-tumor activity against hepatocellular carcinoma in a Phase 1/2 study, along with further Phase 3 evidence of its effectiveness against lung cancer and melanoma.

alt

Read more:

ASCO 2015: Does Hepatocellular Carcinoma Differ in People with Hepatitis B and C?

Liver cancer patients with hepatitis B at a large U.S. cancer center appeared to have worse disease status than those with hepatitis C, including larger tumors and more extensive liver involvement, according to research presented at the American Society of Clinical Oncology (ASCO) annual meeting this month in Chicago. Prognosis for the 2 groups was similar, however.

alt

Read more:

Coverage of the 2014 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2014) in Boston, November 7-11, 2014.

Conference highlights include new interferon-free therapy for hepatitis C -- including options for people with cirrhosis, and liver transplant recipients -- treatment for hepatitis B, and prevention and management of advanced liver disease.

Full listing by topic

The Liver Meeting website

12/2/14

alt